Article
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.
The pharmacogenomics journal - 1 Feb 2016
So D Y F, Wells G A, McPherson R, Labinaz M, Le May M R, Glover C, Dick A J, Froeschl M, Marquis J-F, Gollob M H, Tran L, Bernick J, Hibbert B, Roberts J D
Abstract excerpt
Treatment of carriers of the CYP2C19*2 allele and ABCB1 TT genotype with clopidogrel is associated with increased ischemic complications after percutaneous coronary intervention (PCI). We sought to evaluate a pharmacogenomic strategy among patients undergoing PCI for ST-elevation myocardial infarction (STEMI), by performing a randomized trial, enrolling 102 patients. Point-of-care genetic testing for CYP2C19*2,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.